Ying K. Tam, PhD profile page

Dr. Ying K. Tam, chief scientific officer of Acuitas Therapeutics, is a globally recognized expert in nanotechnology and immunology. He directs Acuitas’ scientific strategy, partnerships and has authored over 100 peer-reviewed studies. As a founding scientist at Acuitas, Dr. Tam has helped establish the company as a leader in lipid nanoparticle (LNP) delivery of nucleic acid therapeutics, contributing to the LNP carriers used in ONPATTRO®, COMIRNATY® – the COVID-19 vaccine – and the first personalized CRISPR therapy.

He earned his MSc and PhD in developmental and molecular biology from the University of Waterloo and completed a post-doctoral fellowship in cancer immunotherapy at the BC Cancer Agency. He has held academic roles, including assistant professor at Rush-Presbyterian-St. Luke’s Medical Center in Chicago and adjunct professor at the University of British Columbia. Before Acuitas, he led the development of an LNP-based immunostimulatory drug at Tekmira Pharmaceuticals.